Synonym
RLX; PD139530; PD-139530; PD 139530; THA-Q; THA Q; THAQ; Deoxydihomo-'c' vasicinone; Deoxydihomo 'c' vasicinone;
IUPAC/Chemical Name
7,8,9,10-Tetrahydroazepino[2,1-b]quinazolin-12-(6H)-one
InChi Key
HTLIIBRHXAULMB-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H14N2O/c16-13-10-6-3-4-7-11(10)14-12-8-2-1-5-9-15(12)13/h3-4,6-7H,1-2,5,8-9H2
SMILES Code
O=C1N2C(CCCCC2)=NC3=C1C=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
214.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Garella R, Squecco R, Baccari MC. Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report. Curr Protein Pept Sci. 2017;18(12):1254-1262. doi: 10.2174/1389203718666170612104719. Review. PubMed PMID: 28606038.
2: Lienart V, Carly B, Kang X, Guzy L, Sajovitz AM, Liebens F. Effect of preventive hormonal therapy on breast density: a systematic qualitative review. ScientificWorldJournal. 2014;2014:942386. doi: 10.1155/2014/942386. Epub 2014 Apr 27. Review. PubMed PMID: 24895676; PubMed Central PMCID: PMC4032660.
3: Lin T, Yan SG, Cai XZ, Ying ZM, Yuan FZ, Zuo X. Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials. Int J Endocrinol. 2014;2014:796510. doi: 10.1155/2014/796510. Epub 2014 Jan 5. Review. PubMed PMID: 24511313; PubMed Central PMCID: PMC3912893.
4: Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013 Nov;76(3):213-20. doi: 10.1016/j.maturitas.2013.06.003. Epub 2013 Jul 11. Review. PubMed PMID: 23849704.
5: D'Amelio P, Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother. 2013 May;14(7):949-56. doi: 10.1517/14656566.2013.782002. Epub 2013 Mar 24. Review. PubMed PMID: 23521229.
6: Calaf Alsina J, Coronado Martín PJ. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action]. Med Clin (Barc). 2013 Mar 16;140(6):266-71. doi: 10.1016/j.medcli.2012.10.006. Epub 2012 Dec 29. Review. Spanish. PubMed PMID: 23276611.
7: Coronado Martín PJ, Calaf Alsina J. [Third generation selective estrogen receptor modulators benefits beyond bone: effects on breast]. Med Clin (Barc). 2013 Mar 2;140(5):217-22. doi: 10.1016/j.medcli.2012.09.032. Epub 2012 Dec 12. Review. Spanish. PubMed PMID: 23246169.
8: Carneiro AL, de Cassia de Maio Dardes R, Haidar MA. Estrogens plus raloxifene on endometrial safety and menopausal symptoms--semisystematic review. Menopause. 2012 Jul;19(7):830-4. doi: 10.1097/gme.0b013e31824a74ce. Review. PubMed PMID: 22549172.
9: Bani D, Bigazzi M. Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf. 2011 Nov 1;6(5):324-8. Review. PubMed PMID: 22424540.
10: Ohta H. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Clin Calcium. 2010 Mar;20(3):315-21. doi: CliCa1003315321. Review. Japanese. PubMed PMID: 20190360.
11: Pearman L, Kagan R, Arsenault J, Muram D. The effects of raloxifene on mammographic breast density: a review of clinical trials. Menopause. 2010 May-Jun;17(3):654-9. doi: 10.1097/gme.0b013e3181c29e56. Review. PubMed PMID: 20032799.
12: Bani D, Yue SK, Bigazzi M. Clinical profile of relaxin, a possible new drug for human use. Curr Drug Saf. 2009 Sep;4(3):238-49. Epub 2009 Sep 1. Review. PubMed PMID: 19534649.
13: Bartol FF, Wiley AA, Bagnell CA. Relaxin and maternal lactocrine programming of neonatal uterine development. Ann N Y Acad Sci. 2009 Apr;1160:158-63. doi: 10.1111/j.1749-6632.2008.03820.x. Review. PubMed PMID: 19416179.
14: Baccari MC, Bani D. Relaxin and nitric oxide signalling. Curr Protein Pept Sci. 2008 Dec;9(6):638-45. Review. PubMed PMID: 19075752.
15: Bani D. Relaxin as a natural agent for vascular health. Vasc Health Risk Manag. 2008;4(3):515-24. Review. PubMed PMID: 18827902; PubMed Central PMCID: PMC2515412.
16: Bartol FF, Wiley AA, Bagnell CA. Epigenetic programming of porcine endometrial function and the lactocrine hypothesis. Reprod Domest Anim. 2008 Jul;43 Suppl 2:273-9. doi: 10.1111/j.1439-0531.2008.01174.x. Review. PubMed PMID: 18638135.
17: Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G. Computerised cognitive behaviour therapy for obsessive-compulsive disorder: a systematic review. Psychother Psychosom. 2007;76(4):196-202. Review. PubMed PMID: 17570957.
18: Matsumoto T. [Selective estrogen receptor modulators (SERMs)]. Clin Calcium. 2006 Sep;16(9):1520-25. Review. Japanese. PubMed PMID: 16951478.
19: Bartol FF, Wiley AA, Bagnell CA. Uterine development and endometrial programming. Soc Reprod Fertil Suppl. 2006;62:113-30. Review. PubMed PMID: 16866313.
20: Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther. 2006 Oct;112(1):38-56. Epub 2006 May 2. Review. PubMed PMID: 16647137.
